MEP6408A - Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću - Google Patents
Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošćuInfo
- Publication number
- MEP6408A MEP6408A MEP-64/08A MEP6408A MEP6408A ME P6408 A MEP6408 A ME P6408A ME P6408 A MEP6408 A ME P6408A ME P6408 A MEP6408 A ME P6408A
- Authority
- ME
- Montenegro
- Prior art keywords
- treatment
- gaba
- activity
- diseases relating
- enhancers
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- -1 steroid compound Chemical class 0.000 abstract 2
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 abstract 1
- 102000005915 GABA Receptors Human genes 0.000 abstract 1
- 108010005551 GABA Receptors Proteins 0.000 abstract 1
- 229940091860 GABA uptake inhibitor Drugs 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002843 gaba uptake inhibitor Substances 0.000 abstract 1
- 230000003371 gabaergic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001743 | 2000-11-20 | ||
| PCT/DK2001/000773 WO2002040009A1 (en) | 2000-11-20 | 2001-11-20 | Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP6408A true MEP6408A (xx) | 2010-02-10 |
Family
ID=8159857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-64/08A MEP6408A (xx) | 2000-11-20 | 2001-11-20 | Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20040024038A1 (ru) |
| EP (1) | EP1337247B1 (ru) |
| JP (1) | JP4152186B2 (ru) |
| KR (1) | KR100865651B1 (ru) |
| CN (1) | CN1318027C (ru) |
| AR (1) | AR031473A1 (ru) |
| AT (1) | ATE336242T1 (ru) |
| AU (2) | AU2002223514B2 (ru) |
| BG (1) | BG107909A (ru) |
| BR (1) | BR0115668A (ru) |
| CA (1) | CA2429220C (ru) |
| CY (1) | CY1106209T1 (ru) |
| CZ (1) | CZ20031383A3 (ru) |
| DE (1) | DE60122368T2 (ru) |
| DK (1) | DK1337247T3 (ru) |
| EA (1) | EA007287B1 (ru) |
| ES (1) | ES2266308T3 (ru) |
| HK (1) | HK1075010A1 (ru) |
| HR (1) | HRP20030404A2 (ru) |
| HU (1) | HUP0400505A3 (ru) |
| IL (1) | IL155587A0 (ru) |
| IS (1) | IS2427B (ru) |
| ME (1) | MEP6408A (ru) |
| MX (1) | MXPA03004349A (ru) |
| NO (1) | NO20032271L (ru) |
| NZ (1) | NZ525520A (ru) |
| PL (1) | PL361051A1 (ru) |
| PT (1) | PT1337247E (ru) |
| SI (1) | SI1337247T1 (ru) |
| SK (1) | SK7682003A3 (ru) |
| UA (1) | UA77403C2 (ru) |
| WO (1) | WO2002040009A1 (ru) |
| YU (1) | YU39003A (ru) |
| ZA (1) | ZA200303289B (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US20050031772A1 (en) * | 2001-11-26 | 2005-02-10 | Frauke Gaedcke | Ginger extract preparation |
| PT1641456E (pt) * | 2003-06-25 | 2010-06-01 | Lundbeck & Co As H | Gaboxadol para o tratamento de depressão e outros distúrbios afectivos |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| CN1976700A (zh) * | 2004-06-29 | 2007-06-06 | H.隆德贝克有限公司 | 神经性疼痛、纤维肌痛或类风湿关节炎的治疗 |
| WO2006012563A2 (en) * | 2004-07-23 | 2006-02-02 | The Regents Of The University Of California | Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
| US20070122507A1 (en) * | 2005-05-26 | 2007-05-31 | Palu Afa K | Histone deacetylase and tumor necrosis factor converting enzyme inhibition |
| WO2008085201A2 (en) * | 2006-12-29 | 2008-07-17 | Prodea Systems, Inc. | Managed file backup and restore at remote storage locations through multi-services gateway device at user premises |
| US20080280983A1 (en) * | 2007-05-09 | 2008-11-13 | Cenerx Biopharma | Methods of treating rett syndrome |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| CN103547240B (zh) * | 2011-06-16 | 2016-03-30 | 索雷斯生命科学公司 | 用于人类自主神经系统的平衡和维持健康的系统和方法 |
| RU2496496C1 (ru) * | 2012-10-04 | 2013-10-27 | Исаак Григорьевич Гитлин | Фармацевтическая композиция, обладающая гамк-ергической активностью |
| EP3481387A4 (en) * | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR102049522B1 (ko) * | 2018-06-05 | 2019-11-27 | 충남대학교산학협력단 | Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물 |
| KR102049526B1 (ko) * | 2018-06-05 | 2019-11-27 | 충남대학교산학협력단 | Gaba를 유효성분으로 하는 항결핵 약학 조성물 |
| WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| EP3883566A4 (en) | 2018-11-21 | 2022-09-07 | Certego Therapeutics Inc. | GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF |
| MX2021007224A (es) | 2018-12-17 | 2021-09-23 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas. |
| CA3138094A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| KR20220114572A (ko) | 2019-12-18 | 2022-08-17 | 오비드 테라퓨틱스 인크. | 1p36 결실 증후군의 치료적 치료를 위한 가복사돌 |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| CN114404437A (zh) * | 2022-03-15 | 2022-04-29 | 山东中医药大学 | 没食子酰芍药苷在制备gabaa受体抑制剂中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4362731A (en) * | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| EP0603312A4 (en) * | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| US5206415A (en) * | 1991-12-20 | 1993-04-27 | Washington University | Tricyclic steroid analogs |
| CZ300694A3 (en) * | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| DE69519945T2 (de) * | 1994-11-23 | 2001-06-07 | Cocensys, Inc. | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
| US5776959A (en) * | 1995-06-05 | 1998-07-07 | Washington University | Anticonvulsant and anxiolytic lactam and thiolactam derivatives |
| ES2235187T3 (es) * | 1995-06-06 | 2005-07-01 | Euro-Celtique S.A. | Esteroides neuroactivos de las series del androstano y el pregnano. |
| IT1290003B1 (it) * | 1997-03-03 | 1998-10-19 | Angelini Ricerche Spa | Uso di pivagabina per preparare composizioni farmaceutiche |
| GB9801208D0 (en) * | 1998-01-21 | 1998-03-18 | Merck Sharp & Dohme | Therapeutic agents |
| PT1098871E (pt) * | 1998-07-22 | 2003-11-28 | Akzo Nobel Nv | Derivados de ester fenilico de alfa-aminoacidos |
| PT1237847E (pt) * | 1999-12-08 | 2006-08-31 | Warner Lambert Co | Metodo para a sintese estereosselectiva de aminoacidos ciclicos |
-
2001
- 2001-11-16 AR ARP010105378A patent/AR031473A1/es unknown
- 2001-11-20 PL PL36105101A patent/PL361051A1/xx unknown
- 2001-11-20 ES ES01996378T patent/ES2266308T3/es not_active Expired - Lifetime
- 2001-11-20 UA UA2003054188A patent/UA77403C2/uk unknown
- 2001-11-20 MX MXPA03004349A patent/MXPA03004349A/es active IP Right Grant
- 2001-11-20 DK DK01996378T patent/DK1337247T3/da active
- 2001-11-20 AU AU2002223514A patent/AU2002223514B2/en not_active Ceased
- 2001-11-20 WO PCT/DK2001/000773 patent/WO2002040009A1/en active IP Right Grant
- 2001-11-20 AU AU2351402A patent/AU2351402A/xx active Pending
- 2001-11-20 KR KR1020037006754A patent/KR100865651B1/ko not_active IP Right Cessation
- 2001-11-20 ME MEP-64/08A patent/MEP6408A/xx unknown
- 2001-11-20 CZ CZ20031383A patent/CZ20031383A3/cs unknown
- 2001-11-20 EP EP01996378A patent/EP1337247B1/en not_active Expired - Lifetime
- 2001-11-20 CN CNB018190936A patent/CN1318027C/zh not_active Expired - Fee Related
- 2001-11-20 AT AT01996378T patent/ATE336242T1/de active
- 2001-11-20 SK SK768-2003A patent/SK7682003A3/sk not_active Application Discontinuation
- 2001-11-20 NZ NZ525520A patent/NZ525520A/en unknown
- 2001-11-20 JP JP2002542383A patent/JP4152186B2/ja not_active Expired - Fee Related
- 2001-11-20 CA CA002429220A patent/CA2429220C/en not_active Expired - Fee Related
- 2001-11-20 IL IL15558701A patent/IL155587A0/xx unknown
- 2001-11-20 BR BR0115668-3A patent/BR0115668A/pt not_active Application Discontinuation
- 2001-11-20 HU HU0400505A patent/HUP0400505A3/hu unknown
- 2001-11-20 EA EA200300594A patent/EA007287B1/ru not_active IP Right Cessation
- 2001-11-20 PT PT01996378T patent/PT1337247E/pt unknown
- 2001-11-20 YU YU39003A patent/YU39003A/sh unknown
- 2001-11-20 DE DE60122368T patent/DE60122368T2/de not_active Expired - Lifetime
- 2001-11-20 SI SI200130619T patent/SI1337247T1/sl unknown
-
2003
- 2003-04-29 ZA ZA2003/03289A patent/ZA200303289B/en unknown
- 2003-04-30 IS IS6803A patent/IS2427B/is unknown
- 2003-05-01 US US10/430,704 patent/US20040024038A1/en not_active Abandoned
- 2003-05-20 HR HR20030404A patent/HRP20030404A2/hr not_active Application Discontinuation
- 2003-05-20 NO NO20032271A patent/NO20032271L/no not_active Application Discontinuation
- 2003-06-13 BG BG107909A patent/BG107909A/bg unknown
-
2005
- 2005-08-23 HK HK05107388A patent/HK1075010A1/xx not_active IP Right Cessation
-
2006
- 2006-10-20 CY CY20061101505T patent/CY1106209T1/el unknown
-
2008
- 2008-06-27 US US12/163,883 patent/US20090143435A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU39003A (sh) | Gaba pojačivači u lečenju bolesti povezanih sa smanjenom neurosteroidnom aktivnošću | |
| DE60329001D1 (en) | 8-hydroxychinolinderivate | |
| MXPA04004370A (es) | Derivados policiclicos de guanina inhibidores de fosfodiesterasa v. | |
| WO2001062234A8 (en) | Dosing regimen | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| HK1094421A1 (en) | (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist | |
| SG166820A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| HK1074573A1 (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
| TW200630086A (en) | Gaba analog prodrug sustained release oral dosage forms | |
| WO2004010987A3 (en) | Use of s1p receptor agonists in heart diseases | |
| WO2004006859A3 (en) | Platinum compound | |
| MXPA04006031A (es) | Compuestos para el tratamiento de trastornos inflamatorios. | |
| AU2002360436A1 (en) | 2-aryl pyrrologpyrimidines for a1 and a3 receptors | |
| MXPA05000765A (es) | Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos. | |
| DE60332663D1 (de) | CCR1-Rezeptor-Antagonisten zur Behandlung u.a. Demyelinisierender entzündlicher Erkrankungen | |
| DE60018186D1 (de) | Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie | |
| IL164528A0 (en) | Method for inhibition of atrophy or for treatment or prevention of atrophy related symptoms in women | |
| IL181713A0 (en) | Use of il-17f for the treatment and/or prevention of neurological diseases | |
| CY1107697T1 (el) | Χρηση της θυλακιοτροπου ορμονης στην μειωση των χρωμοσωμικων ανωμαλιων των σπερματοζωαριων στα αρσενικα | |
| MXPA04011019A (es) | Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias. | |
| PL1828197T3 (pl) | Nowe podstawione pochodne tiofenopirymidynonu jako inhibitory dehydrogenazy 17ß-hydroksysteroidowej | |
| DK1536777T3 (da) | Anvendelse af NF-KB-inhibitorer til behandling af mastitis | |
| DK1421086T3 (da) | 2-(Aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl-derivater med antipsykotisk aktivitet | |
| BR0211340A (pt) | Derivados de 2-(aminometil)-tetraidro-9-oxa-1,3-diaza-ciclopenta[a ]naftalenila com atividade antipsicótica | |
| WO2001066110A3 (en) | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |